Genetic variation associated with chromosomal aberration frequency: A genome-wide association study.


Journal

Environmental and molecular mutagenesis
ISSN: 1098-2280
Titre abrégé: Environ Mol Mutagen
Pays: United States
ID NLM: 8800109

Informations de publication

Date de publication:
01 2019
Historique:
received: 14 03 2018
revised: 18 05 2018
accepted: 03 07 2018
pubmed: 29 10 2018
medline: 15 2 2019
entrez: 29 10 2018
Statut: ppublish

Résumé

Chromosomal aberrations (CAs) in human peripheral blood lymphocytes (PBL) measured with the conventional cytogenetic assay have been used for human biomonitoring of genotoxic exposure for decades. CA frequency in peripheral blood is a marker of cancer susceptibility. Previous studies have shown associations between genetic variants in metabolic pathway, DNA repair and major mitotic checkpoint genes and CAs. We conducted a genome-wide association study on 576 individuals from the Czech Republic and Slovakia followed by a replication in two different sample sets of 482 (replication 1) and 1288 (replication 2) samples. To have a broad look at the genetic susceptibility associated with CA frequency, the sample sets composed of individuals either differentially exposed to smoking, occupational/environmental hazards, or they were untreated cancer patients. Phenotypes were divided into chromosome- and chromatid-type aberrations (CSAs and CTAs, respectively) and total chromosomal aberrations (CAtot). The arbitrary cutoff point between individuals with high and low CA frequency was 2% for CAtot and 1% for CSA and CTA. The data were analyzed using age, sex, occupation/cancer and smoking history as covariates. Altogether 11 loci reached the P-value of 10

Identifiants

pubmed: 30368896
doi: 10.1002/em.22236
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-28

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Yasmeen Niazi (Y)

Department of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Medizinische Fakultät, Universität Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg.

Hauke Thomsen (H)

Department of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.

Bozena Smolkova (B)

Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 84505, Bratislava, Slovakia.

Ludmila Vodickova (L)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.

Sona Vodenkova (S)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

Michal Kroupa (M)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.

Veronika Vymetalkova (V)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.

Alena Kazimirova (A)

Department of Biology, Faculty of Medicine, Slovak Medical University, Limbova 12, 833 03, Bratislava, Slovakia.

Magdalena Barancokova (M)

Department of Biology, Faculty of Medicine, Slovak Medical University, Limbova 12, 833 03, Bratislava, Slovakia.

Katarina Volkovova (K)

Department of Biology, Faculty of Medicine, Slovak Medical University, Limbova 12, 833 03, Bratislava, Slovakia.

Marta Staruchova (M)

Department of Biology, Faculty of Medicine, Slovak Medical University, Limbova 12, 833 03, Bratislava, Slovakia.

Per Hoffmann (P)

Institute of Human Genetics, University of Bonn, D-53127, Bonn, Germany.
Division of Medical Genetics, Department of Biomedicine, University of Basel, 4003, Basel, Switzerland.

Markus M Nöthen (MM)

Institute of Human Genetics, University of Bonn, D-53127, Bonn, Germany.
Department of Genomics, Life & Brain Center, University of Bonn, D-53127, Bonn, Germany.

Maria Dušinská (M)

Health Effects Laboratory, Department of Environmental Chemistry, NILU-Norwegian Institute for Air Research, Instituttveien 18, 2007, Kjeller, Norway.

Ludovit Musak (L)

Clinic of Occupational Medicine and Toxicology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin, Kollarova 2, 03601, Martin, Slovakia.

Pavel Vodicka (P)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.

Kari Hemminki (K)

Department of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Center of Primary Health Care Research, Clinical Research Center, Lund University, 20502, Malmö, Sweden.

Asta Försti (A)

Department of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Center of Primary Health Care Research, Clinical Research Center, Lund University, 20502, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH